Plain-English translation of NCT07101588 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether adding two medications—ruxolitinib and decitabine—to standard pre-transplant chemotherapy can help prevent acute myeloid leukemia from coming back after a stem cell transplant. Early studies suggest this combination is effective at killing leukemia cells while causing fewer serious side effects than traditional treatment alone. The goal is to confirm whether this new approach works better and is safer for patients in their first remission.
Currently, patients with high-risk acute myeloid leukemia who receive stem cell transplants have a high risk of the cancer returning, and standard pre-transplant treatments can cause serious toxicity. This medication combination targets the specific pathways that leukemia cells use to survive, and early results suggest it may reduce relapse rates while shortening the time patients experience low blood counts.
You likely qualify if…
You likely don't qualify if…
You would receive a combination of chemotherapy medications and the new study medications over about two weeks before your stem cell transplant. The new medications (ruxolitinib and decitabine) would be taken alongside standard pre-transplant chemotherapy drugs. After the transplant, you would be monitored closely for side effects and response to treatment, with follow-up visits to check whether the leukemia stays in remission.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China